Biomaterial Database

Thrombogenicity markers in clinical and ex vivo assessment of membrane biocompatibility. 1987

T Bosch, and B Schmidt, and M Blumenstein, and H J Gurland

Department of Nephrology, University of Munich, FRG.

UI	MeSH Term	Description	Entries
D008422	Materials Testing	The testing of materials and devices, especially those used for PROSTHESES AND IMPLANTS; SUTURES; TISSUE ADHESIVES; etc., for hardness, strength, durability, safety, efficacy, and biocompatibility.	Biocompatibility Testing,Biocompatible Materials Testing,Hemocompatibility Testing,Testing, Biocompatible Materials,Testing, Hemocompatible Materials,Hemocompatibility Testings,Hemocompatible Materials Testing,Materials Testing, Biocompatible,Materials Testing, Hemocompatible,Testing, Biocompatibility,Testing, Hemocompatibility,Testing, Materials,Testings, Biocompatibility
D008567	Membranes, Artificial	Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION.	Artificial Membranes,Artificial Membrane,Membrane, Artificial
D010974	Platelet Aggregation	The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.	Aggregation, Platelet
D010978	Platelet Factor 4	A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.	Antiheparin Factor,CXCL4 Chemokine,Chemokine CXCL4,Heparin Neutralizing Protein,PF4 (Platelet Factor 4),gamma-Thromboglobulin,CXCL4, Chemokine,Chemokine, CXCL4,gamma Thromboglobulin
D006435	Renal Dialysis	Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.	Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001620	beta-Thromboglobulin	A platelet-specific protein which is released when platelets aggregate. Elevated plasma levels have been reported after deep venous thrombosis, pre-eclampsia, myocardial infarction with mural thrombosis, and myeloproliferative disorders. Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders.	beta-2 Thromboglobulin,Thromboglobulin, beta-2,beta 2 Thromboglobulin,beta Thromboglobulin
D013927	Thrombosis	Formation and development of a thrombus or blood clot in BLOOD VESSELS.	Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses

Related Publications

T Bosch, and B Schmidt, and M Blumenstein, and H J Gurland

Evaluation of haemodialysis membrane biocompatibility by parallel assessment in an ex vivo model in healthy volunteers.

September 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

T Bosch, and B Schmidt, and M Blumenstein, and H J Gurland

Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients.

December 2003, Kidney international. Supplement,

T Bosch, and B Schmidt, and M Blumenstein, and H J Gurland

Clinical effects of a polyethylene glycol grafted cellulose membrane on thrombogenicity and biocompatibility during hemodialysis.

January 1990, ASAIO transactions,

T Bosch, and B Schmidt, and M Blumenstein, and H J Gurland

[Anti-thrombogenicity of recombinant human thrombomodulin-- ex vivo anti-thrombogenicity and its application to medical materials].

June 1992, [Rinsho ketsueki] The Japanese journal of clinical hematology,

T Bosch, and B Schmidt, and M Blumenstein, and H J Gurland

Ex Vivo and In Vivo Biocompatibility Assessment (Blood and Tissue) of Three-Dimensional Bacterial Nanocellulose Biomaterials for Soft Tissue Implants.

July 2019, Scientific reports,